Immuron Granted US Patent for NASH Treatment

0 Comments 4 view(s)

MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) — Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of gut-mediated diseases, is today pleased to announced that a Notice of Allowance has been received from the United States Patent and Trademarks Office (USPTO) for Immuron’s new patent application (U.S Application No. 13/817,414), entitled “Anti-LPS Enriched Immunoglobulin for Use in treatment and/or Prophylaxis of a Pathological Disorder.”

The patent comprises of a total of ten allowed claims, and is principally directed to a method of treating non-alcoholic steatohepatitis (NASH) with a colostrum-based composition, as developed by Immuron. The market for NASH treatment has come under increased focus, as companies including Bristol-Myers Squibb and Pfizer have referenced efforts to bolster their product development in the sector. According to Reuters, the NASH market is “forecast to be $20 billion to $35 billion as populations with fatty diets increasingly fall victim to a condition with no approved treatments,” further illustrating why the pharmaceutical industry refers to the race to commercialize technology in this sector as “The Dash to NASH.”

“This new patent is a key milestone for Immuron as it further establishes the intellectual property position of our NASH program in the United States and complements the patents already granted in Australia,” said Jerry Kanellos, Interim CEO of Immuron Ltd. “We believe this success paves the way for patent grants in other key jurisdictions, strengthening Immuron’s presence in the global NASH treatment market.”


Jerry Kanellos
Chief Executive Officer (Interim)
Ph: +61 (0)3 9824 5254

Peter Taylor
NWR Communications
Ph: +61 (0)4 1203 6231 


Full story available on